Financial Snapshot

Revenue
$19.69M
TTM
Gross Margin
47.58%
TTM
Net Earnings
-$31.02M
TTM
Current Assets
Q2 2023
Current Liabilities
Q2 2023
Current Ratio
5.69%
Q2 2023
Total Assets
Q2 2023
Total Liabilities
Q2 2023
Book Value
$52.64M
Q2 2023
Cash
Q2 2023
P/E
-0.00002263
Oct 17, 2024 EST
Free Cash Flow
-$1.124M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2022 2021 2020 2019 2018 2015 2014 2013 2012 2011 2010

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2022 2021 2020 2019 2018 2015 2014 2013 2012 2011 2010

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2022 2021 2020 2019 2018 2015 2014 2013 2012 2011 2010

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2022 2021 2020 2019 2018 2015 2014 2013 2012 2011 2010

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2022 2021 2020 2019 2018 2015 2014 2013 2012 2011 2010

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2022 2021 2020 2019 2018 2015 2014 2013 2012 2011 2010

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2022 2021 2020 2019 2018 2015 2014 2013 2012 2011 2010

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $701.81

About Item 9 Labs Corp.

Item 9 Labs Corp. is a vertically integrated cannabis operator and dispensary franchisor. The company is headquartered in Phoenix, Arizona and currently employs 97 full-time employees. The company went IPO on 2011-11-03. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The firm also offers a dispensary franchise model through the national Unity Rd. retail brand. The firm offers approximately 75 active cannabis strains and more than 150 differentiated cannabis vaporizer (vape) products, as well as premium concentrates and Orion vape technologies. The firm's Item 9 Labs brand specializes in select products and user experience across several cannabis categories. The firm operates through two segments: Cultivation and Franchising. Its product lines include Item 9 Labs Flower, Item 9 Labs Concentrates, and Orion 710.

Industry: Dental Equipment & Supplies Peers: DMK PHARMACEUTICALS Corp ALIMERA SCIENCES INC COGNITION THERAPEUTICS INC Hepion Pharmaceuticals, Inc. CUMBERLAND PHARMACEUTICALS INC Endexx Corp JOHNSON & JOHNSON Lipocine Inc. Zynerba Pharmaceuticals, Inc.